NAUT NAUTILUS BIOTECHNOLOGY INC

Nautilus Biotechnology to Participate in B. Riley Securities’ Disruptive Biotech Enabling Technologies – Proteomics, Virtual Conference

Nautilus Biotechnology to Participate in B. Riley Securities’ Disruptive Biotech Enabling Technologies – Proteomics, Virtual Conference

SEATTLE, March 23, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the upcoming B. Riley Securities’ Disruptive Biotech Enabling Technologies – Proteomics, Virtual Conference.

Nautilus’ management is scheduled to participate in a fireside chat on Thursday, April 6th at 10:30 a.m. Pacific Time / 1:30 p.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the company’s website on the “Investors” section of the company website at: .

About Nautilus Biotechnology, Inc.

With its corporate headquarters in Seattle and its research and development headquarters in the San Francisco Bay Area, Nautilus is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. Nautilus’ mission is to transform the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. To learn more about Nautilus, visit .

Media Contact

Investor Contact



EN
23/03/2023

Underlying

NAUTNAUTILUS BIOTECHNOLOGY INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on NAUTILUS BIOTECHNOLOGY INC

 PRESS RELEASE
Free
NAUT NAUTILUS BIOTEC...

Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2025 Fin...

Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2025 Financial Results SEATTLE, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights Continued progress was made in processing and analyzing Tau proteoform samples from collaborators to support platform validation and expanding scientific publications. Externally generated Tau da...

10h / 38m 1 EN
 PRESS RELEASE
Free
NAUT NAUTILUS BIOTEC...

Nautilus Biotechnology Unveils Voyager Platform, Enabling Single-Molec...

Nautilus Biotechnology Unveils Voyager Platform, Enabling Single-Molecule Iterative Mapping, at US HUPO 2026 • Revealed core proteomics instrument during US HUPO 2026 following successful field evaluation at the Buck Institute for Research on Aging • Commercial launch expected to initiate in late 2026, marking a major milestone for next-generation proteomics • Researchers invited to apply to the Early Access Program to use Iterative Mapping, Nautilus’ technology designed to measure billions of intact protein molecules, ahead of broader commercial availability Nautilus Voyager™ Platform ...

February 24, 2026 1 EN
 PRESS RELEASE
Free
NAUT NAUTILUS BIOTEC...

Nautilus Biotechnology to Participate in the TD Cowen 46th Annual Heal...

Nautilus Biotechnology to Participate in the TD Cowen 46th Annual Health Care Conference SEATTLE, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the TD Cowen 46th Annual Health Care Conference. Nautilus’ management is scheduled to participate in a fireside chat on Monday, March 2, 2026, at 10:30 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the ...

February 19, 2026 1 EN
 PRESS RELEASE
Free
NAUT NAUTILUS BIOTEC...

Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2025 F...

Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the fourth quarter and full year 2025 before market open on Thursday, February 26, 2026. The company’s management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business development...

February 5, 2026 1 EN
 PRESS RELEASE
Free
NAUT NAUTILUS BIOTEC...

Nautilus Biotechnology and Weill Cornell Medicine-Qatar Collaborate wi...

Nautilus Biotechnology and Weill Cornell Medicine-Qatar Collaborate with The Michael J. Fox Foundation to Advance Single-Molecule Proteomics Research in Parkinson’s Disease • Support from The Michael J. Fox Foundation for Parkinson’s Research to advance critical research into Parkinson’s disease biology • Nautilus’ development of a single-molecule assay for measuring alpha-synuclein proteoforms is its latest application of Iterative Mapping method to uncover new biological insights• Weill Cornell Medicine-Qatar’s deep chemical biology and neurology expertise and field-leading protein stand...

January 28, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch